Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT followed by QL1706 plus chemotherapy as neoadjuvant therapy in resectable stage II–III driver-gene-negative NSCLC
ChiCTR2500113909Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Major pathologic response (MPR) rate and Event-free survival (EFS). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113909.